Great to see an aficamten trial in children with #HCM

Thanks to all who attended the 1st UCSD Precision Cardiovascular Symposia. It turns out putting scientists clinicians and trialists in a room for 8 hours to talk about heart disease can be quite magical!
Marcus Anthony Urey MD UC San Diego Cardiology UC San Diego Health Sciences

Interesting data Sabiha Gati

Coming up to a decade since the clinical program of mavacamten started.

PIONEER OLE is the open label extension of the original phase II oprn label trial PIONEER-HCM

Here is an interim update over 3 years of mavacamten use in obstructive #HCM
#CardioTwitter

In 10 days we will see the SEQUOIA data -- aficamten vs placebo in 282 patients with obstructive #HCM

1 year data on aficamten in obstructive #HCM from the FOREST-HCM trial. Presented at ACC by Sara Saberi
Here is the poster , follow along
#CardioTwitter

The member of our scientific board Prof. iacopo olivotto always says 'Exercise is the only know drug without side effects.' This new research also points out that it is the most potent one.

🔵 Long-Term Arrhythmic Follow-Up & Risk Stratification: Desmoplakin-Associated ARVC JACC Journals #CardioEd #Cardiology #CardioTwitter

Now just 6 months away! Secure your spot at #HCMSummit8 the definitive global scientific meeting on #hypertrophiccardiomyopathy . Join our 44 esteemed speakers for 3 days (Oct 25-27) in Boston. Seats are limited & going fast. REGISTER: hcmsummit.org. #cardiotwitter #hcm

Our work that firmly establishes that TBX20 truncating variants cause dilated cardiomyopathy (DCM) and left ventricular non-compaction (LVNC) is finally published at ahajournals.org/doi/10.1161/CI…. Roddy Walsh 🇪🇺 🇺🇦 iacopo olivotto Juan Pablo Kaski Andrew Landstrom, MD, PhD Connie Bezzina Pablo Garcia-Pavia Roberto Barriales-Villa

Ethnicity and sudden cardiac death in athletes. Just out on #ejpc . 848 cases, mean age 33 yr. Normal heart at autopsy most common, ACM more common in young black athletes and CAD in young Asian athletes. Full paper:academic.oup.com/eurjpc/advance…

👉In September 2️⃣0️⃣2️⃣5️⃣…we are back!!!! A Coruña 🇪🇸 👉Save the date!!! 😉William J McKenna Ahmad Masri iacopo olivotto Connie Bezzina Juan Pablo Kaski Elena Arbelo Sanjay Sharma Eduard Quintana Juan Pablo Ochoa Pablo Garcia-Pavia Sección Cardiopatías Familiares y Genética CV SEC Ruxandra Jurcut @MTome Tomás Ripoll Vera MD,PhD,FESC🇪🇸 Sección Cardiopatías Familiares y Genética CV SEC …

Ecco il testo integrale del monologo di Antonio #Scurati sul 25 aprile, censurato dalla Rai:

'Giacomo Matteotti fu assassinato da sicari fascisti il 10 di giugno del 1924. Lo attesero sottocasa in cinque, tutti squadristi venuti da Milano, professionisti della violenza assoldati…

patients and organizations. Thanks for following us and for spreading the word. It will be a pleasure to collaborate!
iacopo olivotto Niccolo' Maurizi Hypertrophic Cardiomyopathy Medical Society Wittek Research Foundation for HCM The HCM Academy Anne Dybro Martin Maron, MD Florian Rader, MD, MSc HeartMuscleTalks icardiacnet Thomas Gossios

🧬Gene therapy: 2021 update
MYBPC3 most prevalent gene in HCM, mostly truncated
MYBPC3 deficiency in iPSC➡️lower force, shorter contraction & relaxation times
Therapeutic strategies: CRISPR-Cas9, Exon skipping, trans-splicing, Gene replacement
Thanks Lucie Carrier iacopo olivotto

Proud to be part of this amazing project. Hope to engage in meaningful projects for our patients !

In old #ATTR #amyloidosis patients, #frailty was associated with #KCCQ .
🔴Should we assess #frailty in these patients?
Cappelli Francesco iacopo olivotto andrea ungar
#CardioTwitter #CardioEd
Amyloidosis Amyloidosis Support
doi.org/10.1007/s40520…

The paradigm shift towards cardiomyopathies: all sessions at incredibly high level, overcrowded and passionate ! #ACC2024
And also some living legends…! Martin Maron, MD

What a striking contrast with deep phenotyping approach by Chetan Shenoy
#ACC24

Our Paper Just Published on JACC Journals

Prevalence of Pathogenic Variants
in Cardiomyopathy-Associated Genes in Acute Myocarditis

authors.elsevier.com/a/1issb7tD%7EZ…

Athanasios Bakalakos Giuseppe Limongelli Douglas Cannie